Revolution Medicines (RVMDW) Projected to Post Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMDW) is expected to release its resultson Wednesday, May 6th. Analysts expect Revolution Medicines to post earnings of ($1.8357) per share and revenue of $2.4250 million for the quarter.

Revolution Medicines Price Performance

Revolution Medicines stock traded up $0.35 during midday trading on Monday, hitting $5.05. The company’s stock had a trading volume of 15,495 shares, compared to its average volume of 160,253. Revolution Medicines has a 1-year low of $0.07 and a 1-year high of $6.23. The company has a 50-day moving average price of $2.72 and a two-hundred day moving average price of $1.72.

Revolution Medicines Company Profile

Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.

Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.